← All trials
NCT05457361
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2022
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2023
- First posted
- Jul 14, 2022
- Last posted
- Jul 14, 2022
- Enrollment
- 162
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Southern Medical UniversityLead sponsor
- Hacettepe UniversityCollaborator
- Qingdao UniversityCollaborator
- Peking UniversityCollaborator
- Xiamen UniversityCollaborator
- First People's Hospital of ChenzhouCollaborator
- Southern Medical UniversityCollaborator
- Southern Medical UniversityCollaborator
- Southern Medical UniversityOverall official - principal investigator
- Southern Medical UniversityReponsible party - principal investigator
- Sun Yat-Sen UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- China Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.